EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Infliximab treatment in Crohns disease and antinuclear antibody formation



Infliximab treatment in Crohns disease and antinuclear antibody formation



Gastroenterology 120(5 Supplement 1): A 69, April




(PDF emailed within 1 workday: $29.90)

Accession: 035130763

Download citation: RISBibTeXText



Related references

HACA formation after infliximab treatment in Crohns disease is clearly associated with infusion reactions. Gastroenterology 120(5 Supplement 1): A 621, April, 2001

Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Beh├žet's disease with infliximab. Graefe's Archive for Clinical and Experimental Ophthalmology 250(7): 1081-1087, 2012

Effects of antibodies to infliximab on safety and efficacy of infliximab treatment in patients with Crohns disease. Gastroenterology 122(4 Suppl 1): A 613-A 614, April, 2002

Effect of antibodies to infliximab on infusion reaction and clinical response in patients with fistulizing crohns disease receiving maintenance treatment with infliximab. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No M1598, 2003

Treatment of cutaneous Crohns disease with infliximab. American Journal of Gastroenterology 98(9 Supplement): S250-S251, September, 2003

Crohns disease, infliximab treatment and IgA nephropathy. American Journal of Gastroenterology 98(9 Supplement): S199, September, 2003

Infliximab for treatment of perineal metastatic Crohns disease. Gastroenterology 118(4 Suppl 2 Part 1): AGA A588, April, 2000

Successful treatment of esophageal Crohns disease with infliximab. American Journal of Gastroenterology 95(9): 2419, September, 2000

Infliximab therapy for Crohns disease The Crohns and colitis center of New Jersey experience. Gastroenterology 118(4 Suppl 2 Part 2): AGA A1334, April, 2000

CDP571, A HUMANIZED MONOCLONAL ANTIBODY TO TNF-alpha, A WELL TOLERATED ALTERNATIVE IN CROHNS DISEASE PATIENTS WHO HAVE EXPERIENCED HYPERSENSITIVITY REACTIONS TO INFLIXIMAB. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1357, 2003

Infliximab for the treatment of entero-vesical fistula in Crohns disease. American Journal of Gastroenterology 98(9 Supplement): S145, September, 2003

Efficacy of infliximab in the treatment of korean patients with crohns disease. Korean Journal of Gastroenterology 54(2): 108-116, 2009

Retinal vein thrombosis after infliximab treatment for Crohns disease. American Journal of Gastroenterology 98(4): 939-940, April, 2003